Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

Outcomes for patients with recurrent multiple myeloma (MM) have improved significantly over the past 2 decades with the advent of new targeted therapies and immune therapy-based strategies, such as monoclonal antibodies. Further improvement is expected with introduction of antibody-drug conjugates (ADCs), chimeric antigen receptor (CAR) T cells, and bispecific T cell engagers [1 –3]. Thus far, allogeneic hematopoietic cell transplantation (allo-HCT), the original immune-based therapy, has been a potentially curative therapy in this disease, as indicated by long-term survival data [4,5] via an immune-mediated graft-versus-myeloma (GVM) effect [6].

Source: Biology of Blood and Marrow Transplantation - September 17, 2021 Category: Hematology Authors: Firoozeh Sahebi, Dirk-Jan Eikema, Linda Koster, Nicolaus Kroger, Ellen Meijer, Jaap A. van Doesum, Montserrat Rovira, Yener Koc, Emanuele Angelucci, Didier Blaise, Simona Sammassimo, Andrew McDonald, Concepcion Herrera Arroyo, James F. Sanchez, Edouard Fo Source Type: research